candycrushsodaking| Lepu Bio-B (02157.HK): Three clinical study results announced at the 2024 ASCO Annual Meeting

Gelonghui May 24 丨 Lepu Bio-B (02157candycrushsodaking.HK) issued an announcementcandycrushsodaking, the company's three clinical research results of innovative drug candidates and combination therapies (including the antibody drug conjugate ("ADC") MRG004A, the combination therapy of MRG003 and HX008, and the combination therapy of HX008 and nirapali) were announced at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting.